阿拉丁(688179) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥139,137,019.05, representing a year-on-year increase of 42.96%[2] - Net profit attributable to shareholders for Q3 2024 was ¥25,299,374.57, with a year-on-year growth of 6.42%[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,076,105.37, reflecting a 13.60% increase compared to the same period last year[2] - The net cash flow from operating activities for Q3 2024 was ¥34,256,468.24, showing a significant increase of 110.30%[2] - Total operating revenue for the first three quarters of 2024 reached CNY 377,609,622.39, a significant increase from CNY 282,776,506.57 in the same period of 2023, representing a growth of approximately 33.5%[18] - The net profit for Q3 2024 reached CNY 84,363,039.98, a significant increase of 54% compared to CNY 54,686,877.69 in Q3 2023[20] - Operating profit for Q3 2024 was CNY 94,081,436.19, up from CNY 58,425,975.85 in the same period last year, reflecting a growth of 61%[20] - Total revenue from operating activities for the first nine months of 2024 was CNY 405,242,733.29, compared to CNY 320,407,890.54 in the first nine months of 2023, indicating an increase of 26.5%[23] - The cash flow from operating activities for the first nine months of 2024 was CNY 80,011,604.77, a turnaround from a negative cash flow of CNY -5,757,939.53 in the same period last year[23] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥1,728,284,431.23, marking a 14.79% increase from the end of the previous year[3] - Cash and cash equivalents at the end of Q3 2024 amounted to CNY 512,264,062.68, slightly down from CNY 522,535,290.62 at the end of Q2 2024[15] - Inventory increased to CNY 532,888,943.25 in Q3 2024, up from CNY 442,426,799.55 in Q2 2024, reflecting a growth of approximately 20.5%[15] - Total liabilities increased to CNY 616,910,611.47 in Q3 2024 from CNY 469,150,626.28 in Q2 2024, representing a growth of approximately 31.5%[17] - The company's equity attributable to shareholders rose to CNY 1,039,221,069.90 in Q3 2024, compared to CNY 1,036,402,989.42 in Q2 2024, showing a slight increase[17] - Long-term investments decreased to CNY 2,437,097.71 in Q3 2024 from CNY 2,514,178.48 in Q2 2024, indicating a decline of about 3.1%[15] Research and Development - Research and development expenses totaled ¥15,693,596.95 for Q3 2024, which is 22.65% higher than the same period last year[3] - The proportion of R&D expenses to operating revenue was 11.28%, a decrease of 1.87 percentage points year-on-year[3] - Research and development expenses for Q3 2024 amounted to CNY 45,982,180.25, an increase of 17.5% from CNY 39,151,361.97 in Q3 2023[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,102, with the top 10 shareholders holding a combined 49.43% of shares[10] - Xu Jiuzhen is the largest shareholder, holding 76,832,000 shares, which represents 27.70% of the total shares[11] - The second-largest shareholder, Zhao Liping, holds 41,160,000 shares, accounting for 14.84%[11] - The company has not reported any pledged, marked, or frozen shares among the top shareholders[10] - The report indicates that there are no significant changes in the shareholding structure due to the transfer of shares or other reasons[13] - The company has not received any disclosures regarding related party relationships or concerted actions among the top shareholders[12] - The report does not apply to any significant changes in the top 10 shareholders due to borrowing or returning shares[13] Future Outlook - The company attributed the increase in operating revenue to higher product sales and the consolidation of Yuan Ye Bio into its financial statements[7] - The company expects continued growth in sales revenue and effective cost control to drive future profitability[9] - The report indicates that there are no significant operational issues or reminders for investors[14] - Future outlook includes plans for market expansion and potential new product launches to sustain growth momentum[18] Financial Statements - The financial statements are prepared in RMB and are unaudited as of September 30, 2024[14] - The total comprehensive income for Q3 2024 was CNY 84,386,208.78, compared to CNY 54,686,877.69 in Q3 2023, reflecting an increase of 54%[22] - The company reported a net cash outflow from investing activities of CNY -75,169,929.10 for the first nine months of 2024, compared to CNY -37,768,695.99 in the same period last year[24] - The cash and cash equivalents at the end of Q3 2024 were CNY 509,029,501.30, a decrease from CNY 570,714,358.62 at the beginning of the year[24] - The company incurred financial expenses of CNY 2,054,667.76 in Q3 2024, a significant increase from CNY 284,589.50 in Q3 2023[20]